hiv-1

Documents about hiv-1

• Structural and functional study of CPSF6 in HIV-1 nuclear import#330105HAL (France)
• A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals#390951ClinicalTrials.gov
• Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection#857957ClinicalTrials.gov
• Structure-Guided Exploration of the Divergence of HIV-1 and SRLV Lentiviral Pathways#190886EliScholar
• Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection#238166ClinicalTrials.gov
• Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil#454082ClinicalTrials.gov
• Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults#121459ClinicalTrials.gov
• Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy#827658ClinicalTrials.gov
• Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects#843886ClinicalTrials.gov
• Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1#917827ClinicalTrials.gov
• A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.#28432ClinicalTrials.gov
• Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults#993268ClinicalTrials.gov
• An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children#912283ClinicalTrials.gov
• Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults#967344ClinicalTrials.gov
• CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers#257561HAL (France)
• TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.#866508ClinicalTrials.gov
• A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV#158056ClinicalTrials.gov
• Human papillomavirus vaccine uptake among adolescent girls living with HIV in Côte d’Ivoire: A national cross-sectional survey#137491HAL (France)
• Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults#325160ClinicalTrials.gov
• Monitoring broadly neutralising HIV antibody concentrations using microsampling on dried blood spots in infants#330087HAL (France)
• A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160#381829ClinicalTrials.gov
• Elucidation of early evolution of HIV-1 GroupM in the Congo Basin using computational methods#470009SUNScholar
• Synthesis and characterization of new HIV-1 antiviral agents#651452Dipòsit Digital de la Universitat de Barcelona
• Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors#868730ClinicalTrials.gov
• Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America#911445ClinicalTrials.gov
• Tripterygium Wilfordii Hook F (TwHF) Treatment for Immune Non-responders With HIV-1 Infection#968178ClinicalTrials.gov
• Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)#146251ClinicalTrials.gov
• HIV-1 Tat-driven Glutamate Dysregulation: Implications for Cognitive Impairment in HAND.#284894NCBI PubMed Central
• Increased IFN responses drive myeloid cell activation in people living with HIV-1#301204HAL (France)
• Early HIV-1 maturation drives Env clustering and fusion competence#314830Europe PMC
• HIV-1 protease inhibition potential of functionalized polyoxometalates#403851DataCite
• Conformational variability of HIV-1 Env trimer and viral vulnerability#485122Europe PMC
• Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen#967353ClinicalTrials.gov
• Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients#886098ClinicalTrials.gov
• Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa#197685SUNScholar
• Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.#321545ClinicalTrials.gov
• Self-reported and Point-of-Care Biomarkers of Substance Use Measures Among Older Adults with HIV from Low- and Middle-Income Countries#677190HAL (France)
• Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136#812391ClinicalTrials.gov
• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)#849273ClinicalTrials.gov
• A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy#906256ClinicalTrials.gov
• Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals#424227ClinicalTrials.gov
• Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)#830412ClinicalTrials.gov
• Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)#841561ClinicalTrials.gov
• Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools#844739ClinicalTrials.gov
• Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults#429618ClinicalTrials.gov
• Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults#871319ClinicalTrials.gov
• A Commitment Contract to Achieve Virologic Suppression in Poorly Adherent Patients with HIV/AIDS#214865BYU ScholarsArchive
• Additional file 1 of Secondary distribution of HIV self-test kits by HIV index and antenatal care clients: implementation and costing results from the STAR Initiative in South Africa#452297LSHTM Data Compass
• Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed#864207ClinicalTrials.gov
• A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children#887036ClinicalTrials.gov